Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of December 2020. The report details a corporate action regarding a block listing application submitted to the Financial Conduct Authority and the London Stock Exchange plc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding share issuance rather than a financial performance report.
Material Changes
The material change disclosed is the application to admit 660,000 Ordinary Shares of 25p each to the Official List. These shares are reserved under the GlaxoSmithKline plc Share Save Plan 2012 and the 2017 Deferred Annual Bonus Plan. Upon issuance, these shares will rank pari passu with existing Ordinary Shares.
Guidance, Outlook, and Risks
Admission of the shares is expected to be effective on December 11, 2020. The filing contains no management commentary on financial outlook, risks, contingencies, or unusual items.
Investor Verification Checklist
- Confirm the effective date of the share admission (expected December 11, 2020).
- Verify the total number of shares issued (660,000) and their nominal value (25p each).
- Check the specific employee plans funding the issuance (Share Save Plan 2012 and 2017 Deferred Annual Bonus Plan).
- Review the Official List of the London Stock Exchange for the final admission status.